369 related articles for article (PubMed ID: 1280571)
1. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
Frampton JE; Brogden RN; Langtry HD; Buckley MM
Drugs; 1992 Nov; 44(5):889-917. PubMed ID: 1280571
[TBL] [Abstract][Full Text] [Related]
2. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
Fulton B; Perry CM
Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
[TBL] [Abstract][Full Text] [Related]
3. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
Balfour JA; Benfield P
Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
[TBL] [Abstract][Full Text] [Related]
4. Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
Geddes AM
Drugs; 1991; 42 Suppl 3():34-40. PubMed ID: 1726206
[TBL] [Abstract][Full Text] [Related]
5. Cefpodoxime proxetil in upper respiratory tract infections.
Bergogne-Berezin E
Drugs; 1991; 42 Suppl 3():25-33. PubMed ID: 1726205
[TBL] [Abstract][Full Text] [Related]
6. Microbiological evaluation of cefpodoxime proxetil.
Wiedemann B; Luhmer E; Zühlsdorf MT
Drugs; 1991; 42 Suppl 3():6-12. PubMed ID: 1726210
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with cefpodoxime proxetil in acute otitis media.
Cohen R
Pediatr Infect Dis J; 1995 Apr; 14(4 Suppl):S12-8. PubMed ID: 7792125
[TBL] [Abstract][Full Text] [Related]
8. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections.
Cox CE; Graveline JF; Luongo JM
Drugs; 1991; 42 Suppl 3():41-50. PubMed ID: 1726207
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
Schatz BS; Karavokiros KT; Taeubel MA; Itokazu GS
Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
[TBL] [Abstract][Full Text] [Related]
10. A review of the pharmacokinetics of cefpodoxime proxetil.
Borin MT
Drugs; 1991; 42 Suppl 3():13-21. PubMed ID: 1726203
[TBL] [Abstract][Full Text] [Related]
11. Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin.
Chocas EC; Paap CM; Godley PJ
Ann Pharmacother; 1993 Nov; 27(11):1369-77. PubMed ID: 8286813
[TBL] [Abstract][Full Text] [Related]
12. Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections.
Stevens DL; Pien F; Drehobl M
Diagn Microbiol Infect Dis; 1993 Feb; 16(2):123-9. PubMed ID: 8467623
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].
Xiao YH; Gao L; Li Y; Lü Y; Liu J; Liu Y
Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1867-71. PubMed ID: 15631795
[TBL] [Abstract][Full Text] [Related]
14. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
Perry CM; Scott LJ
Drugs; 2004; 64(13):1433-64. PubMed ID: 15212560
[TBL] [Abstract][Full Text] [Related]
15. [RU 51807 (cefpodoxime proxetil). In vitro and in vivo antibacterial activity of a new orally administered active cephalosporin].
Chantot JF; Mauvais P
Pathol Biol (Paris); 1991 Jan; 39(1):17-27. PubMed ID: 1901403
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME
Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil.
Borin MT; Hughes GS; Patel RK; Royer ME; Cathcart KS
J Clin Pharmacol; 1991 Dec; 31(12):1137-45. PubMed ID: 1761737
[TBL] [Abstract][Full Text] [Related]
18. [Study of the bactericidal effect of cefpodoxime using an in vitro pharmacokinetic model].
Caisson A; Chantot JF
Pathol Biol (Paris); 1991 Oct; 39(8):774-9. PubMed ID: 1762835
[TBL] [Abstract][Full Text] [Related]
19. Cost saving of 5-day therapy with cefpodoxime proxetil versus standard 10-day beta-lactam therapy for recurrent pharyngotonsillitis in adults. A prospective general practice study.
Pelc A; Portier H; Gehanno P; Fiessinger S; Ichou F
Pharmacoeconomics; 1996 Sep; 10(3):239-50. PubMed ID: 10172792
[TBL] [Abstract][Full Text] [Related]
20. Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections.
Safran C
J Antimicrob Chemother; 1990 Dec; 26 Suppl E():93-101. PubMed ID: 2292535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
